within Pharmacolibrary.Drugs.ATC.S;

model S01CA02
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00014166666666666668,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01CA02</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Prednisolone is a synthetic glucocorticoid corticosteroid used primarily for its potent anti-inflammatory and immunosuppressive effects. In combination with antiinfectives in ophthalmic formulations (ATC S01CA02), it is used topically to treat eye inflammation associated with or at risk of bacterial infection. These mixed preparations are available commercially and approved for use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data for topical ocular administration of prednisolone with antiinfectives (ATC S01CA02) are limited in literature. No population PK study reporting standard kinetic parameters for this combination in humans were found as of June 2024. The estimate below is based on available limited data for topical ophthalmic prednisolone formulations in healthy adults.</p><h4>References</h4><ol><li><p>Moksha, L, et al., &amp; Velpandian, T (2021). Pharmacoproteomic analysis of topical dapsone and prednisolone interventions in the aqueous humor of anterior uveitis. <i>Experimental eye research</i> 206 108534–None. DOI:<a href=\"https://doi.org/10.1016/j.exer.2021.108534\">10.1016/j.exer.2021.108534</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33722510/\">https://pubmed.ncbi.nlm.nih.gov/33722510</a></p></li><li><p>Klotz, U (1985). Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. <i>Clinical pharmacokinetics</i> 10(4) 285–302. DOI:<a href=\"https://doi.org/10.2165/00003088-198510040-00001\">10.2165/00003088-198510040-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2864155/\">https://pubmed.ncbi.nlm.nih.gov/2864155</a></p></li><li><p>Johansen, S, et al., &amp; Prause, JU (1996). A bioavailability comparison in rabbits after a single topical ocular application of prednisolone acetate formulated as a high-viscosity gel and as an aqueous suspension. <i>Acta ophthalmologica Scandinavica</i> 74(3) 253–258. DOI:<a href=\"https://doi.org/10.1111/j.1600-0420.1996.tb00087.x\">10.1111/j.1600-0420.1996.tb00087.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8828722/\">https://pubmed.ncbi.nlm.nih.gov/8828722</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01CA02;
